<DOC>
	<DOCNO>NCT02201394</DOCNO>
	<brief_summary>ACS patient treat antiplatelet drug require CABG surgery wait 5-7 day effect drug wean . This treatment-devoid period leave patient vulnerable , therefore mean shorten period could useful . The present study aim investigate possibility reverse antiplatelet effect ticagrelor help fresh donor platelet . Fresh platelet add blood sample treat patient vary concentration specific timepoints determine time amount fresh platelet need normalize platelet reactivity treat sample .</brief_summary>
	<brief_title>Reversing Ticagrelor 's Effects With Fresh Platelets</brief_title>
	<detailed_description>The current ACC/AHA guideline ACS patient require CABG surgery treatment dual antiplatelet therapy recommend delay surgery 5-7 day discontinuation therapy , allow dissipation antiplatelet effect . This treatment-devoid waiting period put ACS patient risk cardiovascular event . Any mean shorten vulnerable period would critical value . One possibility speed recovery inhibit platelet administer infusion fresh platelet . In fact , platelet transfusion frequently administer patient surgery receive prior antiplatelet therapy . However , degree transfusion restore platelet function recipient subject ' blood time dose effective unknown . The timing critical scenario urgent surgery require infusion platelet soon antiplatelet dose could render useless residual drug circulation . The aim present study investigate restoration platelet function ticagrelor-treated subject add donor platelet blood . The study would 2 arm mimic different clinical scenario : 1 . Clinical Scenario 1 - Patient give load dose ( LD ) ticagrelor emergency room , require surgery : A single ( 180 mg ) LD ticagrelor aspirin 325 mg give study subject platelet test perform addition fresh platelet blood ex vivo . Donor platelets add 4- , 6- , 24- 48-hours post-dose , assess time require normalize subject 's platelet function LD ticagrelor . 2 . Clinical Scenario 2 - Patient maintenance dosing ( MD ) ticagrelor , require surgery : Subjects receive 3-7 day ticagrelor ( 90 mg BID ) aspirin ( 81 mg OD ) . After last dose , platelet test perform addition fresh platelet blood ex vivo , 4- , 6- , 24- 48-hours post-dose ass time require normalize subject 's platelet function LD ticagrelor Platelet test carry use follow methodology : 1 . Platelet Aggregation - VerifyNow P2Y12 assay . 2 . Platelet Aggregation - Multiplate Analyzer .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Male female volunteer 18 75 year old . History stable ( i.e . nonacute ) cardiovascular disease presence risk factor cardiovascular disease ( i.e . hypertension , diabetes , hyperlipidemia , high calcium score abnormal finding angiography stress test ) . Conditions associate hemorrhagic risk , e.g. , frequent epistaxis , gastrointestinal ulcer , hemorrhagic vascular lesion , recent surgery . Allergy hypersensitivity aspirin ticagrelor . Loss &gt; 400 mL blood blood donation within past 3 month . Positive serology hepatitis B ( HBs Ag ) hepatitis C. History drug abuse alcohol abuse . Positive pregnancy test . Evidence unstable acute cardiovascular disease ( e.g. , unstable angina , recent myocardial infarction , congestive heart failure ) . History clinically relevant pulmonary , hepatic , gastrointestinal , renal , metabolic , hematologic , neurologic , respiratory psychiatric disease , bleeding , acute infectious disease sign acute illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Antiplatelet</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Platelets</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Coronary artery disease .</keyword>
</DOC>